Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
With regard to their GC use (history), those who used MTX had a higher cumulative GC dose, a longer cumulative duration of GC use, but were now using a lower dose than those without MTX use.Demographics and clinical features of the 188 patients with polymyalgia rheumatica and vasculitides stratified by MTX useOverall (n = 188)No MTX use (n = 142)MTX use (n = 44)SMDGeneral information Age, years68.10 (10.94)67.81 (10.98)69.02 (10.89)0.111 Female sex, n (%)124 (66.7)98 (69.0)26 (59.1)0.208 BMI, score26.57 (4.46)26.31 (4.37)27.42 (4.69)0.245 Disease duration, years2.82[0.90, 8.56]1.80[0.83, 7.03]4.67[2.02, 9.49]0.205 Health assessment questionnaire, score0.25[0.00, 1.00]0.12[0.00, 1.00]0.25[0.00, 0.88]0.008 Regular physical exercise, n (%)93 (49.5)75 (52.8)18 (40.9)0.240 Alcohol consumption, n (%)0.042 None76 (41.8)58 (41.7)18 (41.9) Irregular/infrequent79 (43.4)60 (43.2)19 (44.2) Occasional23 (12.6)18 (12.9)5 (11.6) Frequent4 (2.2)3 (2.2)1 (2.3) C-reactive protein levels, mg/l4.80[1.35, 11.00]3.90[1.22, 11.40]5.40[1.60, 9.60]0.021 25-(OH)-Vitamin D in nmol/l84.13 (25.50)81.94 (27.23)89.91 (19.32)0.338 History of vertebral fractures19 (10.2)15 (10.6)4 (9.1)0.049 History of fractures due to inadequate trauma62 (33.3)45 (31.7)17 (38.6)0.146Treatment and comedication Current GC dose, mg/d prednisone equivalent*7.50[4.00, 20.00]10.00[4.00, 28.75]5.00[2.15, 10.00]0.385 Cumulative GC dose, mg5963.50[1825.00, 15,743.78]5393.75 [1521.25, 12,423.62]8946.88[3315.00, 17,526.25]0.056 Cumulative duration of GC use, years2.08[0.33, 6.93]1.52[0.22, 6.28]3.13[0.97, 7.98]0.082 Proton pump inhibitor intake, n (%)109 (58.6)83 (58.5)26 (59.1)0.013 Data on MTX useNA Current MTX dose, mg/week15[10; 15] Cumulative MTX dose, g1.46[0; 5.37] Subcutaneous administration, n (%)117 (38.6) Current dose of s.c. users, mg/week15[12.5; 17.5] Oral administration, n (%)126 (59.1) Current dose of oral users, mg/week11.25[3.75; 18.75]Numbers are mean (standard deviation) or median (interquartile range) unless otherwise specified.
Source: Baseline characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides: a cross-sectional analysis with dose: response analyses
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides: a cross-sectional analysis with dose-response analyses
Cross-sectional study · Rheumatology International · 2023
Original publication title
No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides: a cross-sectional analysis with dose: response analyses
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To investigate whether methotrexate (MTX) use is associated with bone mineral density (BMD) in patients with polymyalgia rheumatica (PMR) and various forms of vasculitis.
Source: ObjectiveAbstract: What methods does the paper describe?
Rh-GIOP is a cohort study designed to evaluate bone health in patients with inflammatory rheumatic diseases. This cross-sectional analysis assessed the baseline visits of all patients with PMR or any kind of vasculitis. Following univariable analysis, multivariable linear regression analysis was performed. The lowest T-score of either the lumbar spine or the femur was chosen as the dependent variable to examine the relationship between MTX use and BMD. These analyses were adjusted for a variety of potential confounders, including age, sex, and glucocorticoid (GC) intake.
Source: MethodsAbstract: Results
Of 198 patients with PMR or vasculitis, 10 patients were excluded for very high GC dose (n = 6) or short disease duration (n = 4). The remaining 188 patients had the following diseases: PMR 37.2%, giant cell arteritis 25.0%, granulomatosis with polyangiitis 16.5%, followed by rarer diseases. The mean age was 68.0 ± 11.1 years, mean disease duration was 5.58 ± 6.39 years, and 19.7% had osteoporosis by dual x-ray absorptiometry (T-score ≤ −2.5). 23.4% were taking MTX at baseline with a mean dose of 13.2 mg/week (median: 15 mg/week). 38.6% of those used a subcutaneous preparation.
MTX users had similar BMD compared to non-users (minimum T-scores −1.70 (± 0.86) versus −1.75 (± 0.91), respectively; p = 0.75). There was no statistically significant dose: response relationship: neither current nor cumulative dose were associated with BMD in unadjusted or adjusted models (current dose: slope −0.02; −0.14 to 0.09; p = 0.69; cumulative dose: slope −0.12; −0.28 to 0.05; p = 0.15).
Source: ResultsAbstract: Conclusion
In the Rh-GIOP cohort, MTX is used in about a quarter of patients with PMR or vasculitis. It is not associated with BMD levels.
Source: ConclusionAuthors’ abstract
Objective
To investigate whether methotrexate (MTX) use is associated with bone mineral density (BMD) in patients with polymyalgia rheumatica (PMR) and various forms of vasculitis.
Methods
Rh-GIOP is a cohort study designed to evaluate bone health in patients with inflammatory rheumatic diseases. This cross-sectional analysis assessed the baseline visits of all patients with PMR or any kind of vasculitis. Following univariable analysis, multivariable linear regression analysis was performed. The lowest T-score of either the lumbar spine or the femur was chosen as the dependent variable to examine the relationship between MTX use and BMD. These analyses were adjusted for a variety of potential confounders, including age, sex, and glucocorticoid (GC) intake.
Results
Of 198 patients with PMR or vasculitis, 10 patients were excluded for very high GC dose (n = 6) or short disease duration (n = 4). The remaining 188 patients had the following diseases: PMR 37.2%, giant cell arteritis 25.0%, granulomatosis with polyangiitis 16.5%, followed by rarer diseases. The mean age was 68.0 ± 11.1 years, mean disease duration was 5.58 ± 6.39 years, and 19.7% had osteoporosis by dual x-ray absorptiometry (T-score ≤ −2.5). 23.4% were taking MTX at baseline with a mean dose of 13.2 mg/week (median: 15 mg/week). 38.6% of those used a subcutaneous preparation.
MTX users had similar BMD compared to non-users (minimum T-scores −1.70 (± 0.86) versus −1.75 (± 0.91), respectively; p = 0.75). There was no statistically significant dose: response relationship: neither current nor cumulative dose were associated with BMD in unadjusted or adjusted models (current dose: slope −0.02; −0.14 to 0.09; p = 0.69; cumulative dose: slope −0.12; −0.28 to 0.05; p = 0.15).
Conclusion
In the Rh-GIOP cohort, MTX is used in about a quarter of patients with PMR or vasculitis. It is not associated with BMD levels.
Publication and source details
Original title: No association between methotrexate and impaired bone mineral density in a cohort of patients with polymyalgia rheumatica, giant cell arteritis, granulomatosis with polyangiitis and other vasculitides: a cross-sectional analysis with dose: response analyses
Andriko Palmowski; Mitsuteru Akahoshi; Burkhard Muche; Zhivana Boyadzhieva; Sandra Hermann; Chikashi Terao; Edgar Wiebe; Frank Buttgereit
Rheumatology International · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Rh-GIOP is or was supported by a joint funding from Abbvie, Amgen, Almirall, Biogen, BMS, Chugai, Galapagos, Generic Assays, GSK, Hexal, Horizon Therapeutics, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche and Sanofi.Charité: Universitätsmedizin Berlin (3093)Open Access funding enabled and organized by Projekt DEAL.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T20:28:11.584630+00:00
DOI: 10.1007/s00296-023-05286-6 · PMC10073043